Hair loss is a potential but uncommon side effect of Humira (adalimumab). Hair loss wasn’t reported during the drug’s studies, but has been reported since Humira was approved for use. Humira is a ...

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

If you want to accentuate the importance of a problem, it seems sensible to explain how prevalent it is. Lots of people are at risk of Alzheimer’s disease. Lots of women carry a gene that makes them ...

Blue Shield of California has cut the price it will pay for a biosimilar of the drug Humira. Blue Shield will purchase the medicine used to treat certain autoimmune and inflammatory diseases, such as ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...